Q-REstrain consists of microRNA molecules with the ability to regulate the gene expression of a specific target. The short dsRNAs (double-stranded RNAs) are derived by cleavage of long dsRNA from Dicer and can be microRNAs (miRNAs). miRNAs then assemble with RNA-induced silencing complex (RISC) and cause gene silencing. RNAi has been used in the therapy of different diseases including cancer, viral infections, respiratory diseases, etc. Targeting of specific proteins, through degradation of their mRNA, is very common in cancer treatment of different types of cancer or other infections.
Q-REstrain contains microRNAs isolated by the patient’s sample, leading to the degradation of specific mRNA molecules, which are overexpressed in this specific sample, thus regulating the expression. Q-REstrain is for autologous use only and is provided through the RGCC network.
The members of our international tumor board are renowned physicians, naturopaths, scientists, and experienced clinical practitioners from Switzerland (8), Germany (6), the USA (3), Japan (2), England (1), the United Arab Emirates (1), Malaysia (1), the Netherlands (1), and Australia (1) with a wealth of knowledge and experience. This team of experts covers the medical fields of oncological surgery, urology, medical oncology, interventional radiology, radiation therapy, cancer immunology, cancer genetics, stem cell transplantation, internal medicine, cardiology, anesthesiology and interventional pain therapy, naturopathy, integrative medicine, functional nutrition, herbal medicine, and oncological nursing.
Depending on the needs of an individual cancer patient, specific members of our international, multidisciplinary tumor board are involved in formulating the best possible cancer treatment plan, offering second opinion services, and conducting follow-up consultations for disease monitoring for further diagnosis and treatment. Direct referral to one of these specialists is possible.
Fast order processing
